Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety study of QX005N in adults with moderate-to-severe atopic dermatitis
ChiCTR2300072175Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QX005N in atopic dermatitis (AD), sponsored by Peking Union Medical College Hospital. Primary endpoint: Incidence of adverse events. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
QX005N
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on ChiCTR2300072175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072175.